



Figure S1



Legend to Supplementary Figure 1:

Two ER+/PR- mammary tumors from *Neu+Tip30^{-/-}* mice were minced and inoculated s.c. in the front flanks of ovariectomized mice supplemented with Placebo (n = 10), estrogen (E2, n = 6), progesterone (P4, n = 6) or E2 plus P4 (n = 7) pellets. Kaplan-Meier analysis of mammary-tumor free-survival was performed based on the time of tumors becoming 1 cm³ in volume or tumors becoming ≥ 0.25 cm³ by the end of three months. $P = 0.009$ (placebo vs. E2 + P4), log-rank test.

Figure S2



Legend to Supplementary Figure 2:

(A) Representative immunohistochemical staining images show enhanced phosphorylation of ERK1/2 at Thr202/Tyr204 in mammary tumors from Neu+/Tip30^{-/-} mice (n = 3) compared with those from Neu+/Tip30^{+/+} mice (n = 3).

(B) Quantification of pERK1/2 positive cells. Since very few cells at the tumor core were stained positive for pERK, cells within 120 μ m distance from the edge were counted. $P = 0.005$; t test.